The stock will trade on the upcoming Phase 2 data readouts, not the quarterly financials. The TibuSHIELD topline data in Q4 2026 is the primary catalyst. The expanded pipeline (PMR) and strong cash runway provide a positive narrative, but binary risk remains until efficacy data is released. Monitor for any early leaks or analyst previews ahead of the Q4 readout.
Price Chart
Executive Summary
Zura Bio reported Q2 2026 financial results with a net loss of $26.3M ($0.21/share), wider than the $16.0M loss in Q2 2025, driven by increased R&D spending on tibulizumab clinical programs. The key catalysts are the completion of enrollment in both Phase 2 trials (TibuSHIELD and TibuSURE), exceeding targets, and the announcement of a third Phase 2 indication (PMR) to be initiated by year-end. The company has $205.1M in cash, sufficient to fund operations through at least end of 2028, de-risking the path to upcoming data readouts in Q4 2026 and H1 2027.
Key Financial Metrics
Key Facts
- Enrollment completed in TibuSHIELD (HS) with 247 participants, exceeding the initial target of ~225.
- Enrollment completed in TibuSURE (SSc) with 91 participants, exceeding the initial target of ~80.
- Announced plans to initiate a Phase 2 study (NEXUS-PMR) for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026.
- Cash and cash equivalents of $205.1M as of June 30, 2026, expected to fund operations through at least end of 2028.
- Net loss for Q2 2026 was $26.3M ($0.21/share), vs $16.0M ($0.17/share) in Q2 2025.
- R&D expenses increased to $20.7M in Q2 2026 from $8.7M in Q2 2025, driven by Phase 2 trial advancement.
Financial Impact
Net loss widened by $10.3M YoY to $26.3M; cash burn of ~$20.4M in Q2 2026 (from $225.6M to $205.1M).
Risk Factors
- Phase 2 topline data for tibulizumab in HS (Q4 2026) and SSc (H1 2027) are binary events with potential for failure.
- Net loss is widening as R&D spending increases, with no revenue expected in the near term.
- Competition in HS from approved IL-17 inhibitors (secukinumab, bimekizumab) and other novel mechanisms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001855644-26-000007 |
| Document: corporatedeck_zurabiox11.htm | 0001855644-26-000007 |
| Document: zura-20260811.htm | 0001855644-26-000007 |
| Document: 0001855644-26-000007-index-headers.html | 0001855644-26-000007 |
| Document: 0001855644-26-000007-index.html | 0001855644-26-000007 |
| Document: 0001855644-26-000007.txt | 0001855644-26-000007 |
| 8-K Data (Synthetic) | 0001855644-26-000007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $3.35 | awaiting T+20 | — | $3.85 (+14.93%) |
Aug 17, 2026 10w ago | 8-K | $5.68 $4.93 | ▼ −13.20% | ▼ −11.23% | $3.85 (−32.22%) |
Aug 11, 2026 11w ago | 8-K | $5.56 $5.71 | ▲ +2.70% | ▲ +3.76% | $3.85 (−30.76%) |
Jul 1, 2026 16w ago | 8-K | $5.01 $5.31 | ▲ +6.09% | ▲ +8.28% | $3.85 (−23.08%) |
Jun 18, 2026 18w ago | 8-K | $4.23 $5.45 | ▲ +28.84% | ▲ +28.99% | $3.85 (−8.98%) |
May 7, 2026 24w ago | 8-K | $4.54 $3.86 | ▼ −14.98% | ▼ −18.11% | $3.85 (−15.20%) |
Mar 5, 2026 33w ago | 8-K | $6.76 $6.03 | ▼ −10.80% | ▼ −7.01% | $3.85 (−43.05%) |
Feb 26, 2026 34w ago | 8-K | $6.77 $6.04 | ▼ −10.78% | ▼ −4.38% | $3.85 (−43.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers